A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group Study
- 1 September 1988
- journal article
- conference paper
- Published by Springer Nature in Investigational New Drugs
- Vol. 6 (3) , 223-226
- https://doi.org/10.1007/bf00175403
Abstract
Cisplatin was given intravenously to 35 evaluable patients with unresectable malignant mesothelioma on Southwest Oncology Group (SWOG) Study 8418. Five patients (14.3%) achieved partial response with median response duration of six months (range 2–12 months); eleven patients (31.4%) had stable disease of median duration of 5.5. months (range 2–21 months). Median survival for all patients was 7.5 months, 9 months for responders. Toxicity was as expected except that 12 patients (34.2%) discontinued cisplatin because of side effects. Cisplatin has moderate activity in mesothelioma and further studies with platinum analogues should be pursued.Keywords
This publication has 4 references indexed in Scilit:
- Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study.Journal of Clinical Oncology, 1987
- Cisplatin administered by the intracavitary route as treatment for malignant mesotheliomaCancer, 1986
- Treatment of six cases of mesothelioma with doxorubicin and cisplatinCancer, 1983